Highlights NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Market Closed - NSE India S.E. Other stock markets 12:43:53 13/05/2024 BST			5-day change	1st Jan Change
974.5 ^INR	+0.05%		-5.76%	+20.11%

05-08	AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	MT
05-08	AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	05-08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	05-08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	05-08	MT
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	04-09	MT
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	02-15	CI
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	02-14	CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	11-14	MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	11-14	CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	11-02	MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%	08/09/23	MT
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit	06/09/23	RE
Natco Pharma to Form UK Arm	09/08/23	MT
NATCO Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09/08/23	CI
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24	09/08/23	CI
Natco Pharma Limited Receives Final Approval for Tipiracil Hydrochloride and Trifluridine (Generic for LonsurfÂ®) for the US Market	16/06/23	CI
Natco Pharma Gets US FDA's Establishment Inspection Report After Vizag Unit Inspection	16/06/23	MT
NATCO Pharma Seeks Acquisitions	06/06/23	CI
NATCO Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Highlights

Filters